Showing 801-820 of 8875 for: Cochrane Systematic Reviews Back
- Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery
Cochrane Systematic Reviews, 15-Jun-2011
Peripheral arterial disease (PAD) is frequently treated by either an infrainguinal autologous (using the patient's own veins) or synthetic graft bypass. The rate of occlusion of the graft after one year is between 12% and 60%. To prevent occlusion, patien
- Antithrombotic drugs for carotid artery dissection
Cochrane Systematic Reviews, 6-Mar-2011
Extracranial internal carotid artery dissection (eICAD) is a leading cause of stroke in younger patients.
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
Cochrane Systematic Reviews, 28-Sep-2021
Multiple myeloma is a malignant plasma cell disorder characterised by clonal plasma cells that cause end-organ damage such as renal failure, lytic bone lesions, hypercalcaemia and/or anaemia. People with multiple myeloma are treated with immunomodulatory
- Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction
Cochrane Systematic Reviews, 17-Jul-2013
Pregnancy complications such as pre-eclampsia and eclampsia, intrauterine growth restriction and placental abruption are thought to have a common origin related to abnormalities in the development and function of the placenta.
- Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia
Cochrane Systematic Reviews, 13-Jul-2022
Cerebral small vessel disease is a progressive disease of the brain's deep perforating blood vessels. It is usually diagnosed based on lesions seen on brain imaging. Cerebral small vessel disease is a common cause of stroke but can also cause a progressiv
- Antithrombotic treatment after stroke due to intracerebral haemorrhage
Cochrane Systematic Reviews, 26-Jan-2023
This is an update of the Cochrane Review last published in 2017. Survivors of stroke due to intracerebral haemorrhage (ICH) are at risk of major adverse cardiovascular events (MACE). Antithrombotic (antiplatelet or anticoagulant) treatments may lower the
- Antithyroid drug regimen for treating Graves' hyperthyroidism
Cochrane Systematic Reviews, 20-Jan-2010
Antithyroid drugs are widely used in the therapy of hyperthyroidism. There are wide variations in the dose, regimen or duration of treatment used by health professionals.
- Anti‐TNF agents for paediatric psoriasis
Cochrane Systematic Reviews, 24-Nov-2015
Psoriasis is a chronic skin disease that may develop at any age. Estimates for the United States and Europe suggest that psoriasis accounts for 4% of skin diseases in children. In most cases, the condition is mild and can be treated with creams. However,
- Anti‐TNF‐α treatment for pelvic pain associated with endometriosis
Cochrane Systematic Reviews, 28-Mar-2013
Endometriosis is a chronic, recurring condition that can develop during the reproductive years. It is characterised by the development of endometrial tissue outside the uterine cavity. It is the most common cause of pelvic pain in women. This endometrial
- Anti‐tuberculous therapy for maintenance of remission in Crohn's disease
Cochrane Systematic Reviews, 22-Jul-2016
There have been a number of studies with conflicting results which have examined the effect of anti-tuberculous therapy in Crohn's disease. A meta-analysis was performed to evaluate the use of anti-tuberculous therapy for the maintenance of remission in C
- Antitumour antibiotic containing regimens for metastatic breast cancer
Cochrane Systematic Reviews, 18-Oct-2004
Antitumour antibiotics are used in the management of metastatic breast cancer. Some of these agents have demonstrated higher tumour response rates than non-antitumour antibiotic regimens, however a survival benefit has not been established in this setting
- Anti‐tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non‐infectious uveitis
Cochrane Systematic Reviews, 18-Dec-2018
Non-infectious uveitis describes a heterogenous group of ocular disorders characterised by intraocular inflammation in the absence of infection. Uveitis is a leading cause of visual loss, most commonly due to uveitic macular oedema (UMO). Treatment is aim
- Anti‐vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity
Cochrane Systematic Reviews, 8-Jan-2018
Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in foetal life. Researchers have recently attempted to use anti-VEGF agents for the treatment of retinopathy of prematurity (ROP), a vasoproliferative disorder. The safety and effi
- Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema
Cochrane Systematic Reviews, 18-Apr-2018
The combination of steroid and anti-vascular endothelial growth factor (VEGF) intravitreal therapeutic agents could potentially have synergistic effects for treating diabetic macular oedema (DMO). On the one hand, if combined treatment is more effective t
- Anti‐vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia
Cochrane Systematic Reviews, 15-Dec-2016
Choroidal neovascularisation (CNV) is a common complication of pathological myopia. Once developed, most eyes with myopic CNV (mCNV) experience a progression to macular atrophy, which leads to irreversible vision loss. Anti-vascular endothelial growth fac
- Anti‐vascular endothelial growth factor for control of wound healing in glaucoma surgery
Cochrane Systematic Reviews, 15-Jan-2016
Trabeculectomy is performed as a treatment for glaucoma to lower intraocular pressure (IOP). The surgical procedure involves creating a channel through the wall of the eye. However scarring during wound healing can block this channel which will lead to th
- Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis
Cochrane Systematic Reviews, 16-Oct-2018
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor (anti-VEGF) can reduce oedema, improve vision and prevent further visual loss. These drugs have replaced la
- Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion
Cochrane Systematic Reviews, 7-Jul-2020
Branch retinal vein occlusion (BRVO) is one of the most commonly occurring retinal vascular abnormalities. The most common cause of visual loss in people with BRVO is macular oedema (MO). Grid or focal laser photocoagulation has been shown to reduce the r
- Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion
Cochrane Systematic Reviews, 1-May-2014
Central retinal vein occlusion (CRVO) is a relatively common retinal vascular disorder in which macular oedema may develop, with a consequent reduction in visual acuity. Until recently there has been no treatment of proven benefit, but growing evidence su
- Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration
Cochrane Systematic Reviews, 4-Mar-2019
Age-related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to AMD accounts for most cases of AMD-related severe
